Analysts forecast that Nektar Therapeutics (NASDAQ:NKTR) will announce earnings per share of ($0.65) for the current fiscal quarter, according to Zacks Investment Research. Five analysts have issued estimates for Nektar Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.78) and the highest estimate coming in at ($0.52). Nektar Therapeutics posted earnings per share of ($0.14) in the same quarter last year, which would indicate a negative year over year growth rate of 364.3%. The firm is scheduled to issue its next quarterly earnings results on Thursday, March 7th.
According to Zacks, analysts expect that Nektar Therapeutics will report full-year earnings of $3.57 per share for the current financial year, with EPS estimates ranging from $3.22 to $3.82. For the next financial year, analysts expect that the company will report earnings of ($0.98) per share, with EPS estimates ranging from ($2.69) to $4.42. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that follow Nektar Therapeutics.
Nektar Therapeutics (NASDAQ:NKTR) last announced its quarterly earnings data on Wednesday, November 7th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.63) by $0.07. The firm had revenue of $27.80 million during the quarter, compared to analyst estimates of $26.08 million. Nektar Therapeutics had a net margin of 65.69% and a return on equity of 174.70%. The business’s quarterly revenue was down 81.8% on a year-over-year basis. During the same period in the previous year, the business posted $0.37 EPS.
In other Nektar Therapeutics news, Director Dennis L. Winger sold 34,250 shares of the company’s stock in a transaction on Tuesday, August 14th. The shares were sold at an average price of $60.60, for a total value of $2,075,550.00. Following the completion of the transaction, the director now directly owns 59,875 shares in the company, valued at approximately $3,628,425. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director R Scott Greer sold 10,000 shares of the company’s stock in a transaction on Tuesday, September 4th. The stock was sold at an average price of $67.39, for a total transaction of $673,900.00. Following the completion of the transaction, the director now owns 140,333 shares of the company’s stock, valued at $9,457,040.87. The disclosure for this sale can be found here. Insiders have sold a total of 96,000 shares of company stock valued at $5,825,680 over the last quarter. 4.31% of the stock is currently owned by company insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. FMR LLC raised its holdings in Nektar Therapeutics by 6.7% in the 2nd quarter. FMR LLC now owns 25,705,902 shares of the biopharmaceutical company’s stock worth $1,255,220,000 after purchasing an additional 1,608,834 shares in the last quarter. OppenheimerFunds Inc. raised its holdings in Nektar Therapeutics by 7.9% in the 2nd quarter. OppenheimerFunds Inc. now owns 11,560,779 shares of the biopharmaceutical company’s stock worth $564,512,000 after purchasing an additional 845,257 shares in the last quarter. First Trust Advisors LP raised its holdings in Nektar Therapeutics by 176.2% in the 3rd quarter. First Trust Advisors LP now owns 2,068,900 shares of the biopharmaceutical company’s stock worth $126,120,000 after purchasing an additional 1,319,776 shares in the last quarter. Frontier Capital Management Co. LLC raised its holdings in Nektar Therapeutics by 18.8% in the 3rd quarter. Frontier Capital Management Co. LLC now owns 1,298,286 shares of the biopharmaceutical company’s stock worth $79,144,000 after purchasing an additional 205,891 shares in the last quarter. Finally, Carillon Tower Advisers Inc. raised its holdings in Nektar Therapeutics by 41.2% in the 2nd quarter. Carillon Tower Advisers Inc. now owns 1,017,300 shares of the biopharmaceutical company’s stock worth $49,674,000 after purchasing an additional 296,875 shares in the last quarter. Institutional investors and hedge funds own 92.72% of the company’s stock.
Shares of NKTR traded down $2.64 during mid-day trading on Thursday, reaching $35.31. The company’s stock had a trading volume of 4,322,822 shares, compared to its average volume of 3,121,603. The firm has a market cap of $6.22 billion, a price-to-earnings ratio of -64.20 and a beta of 2.91. The company has a debt-to-equity ratio of 0.13, a quick ratio of 19.55 and a current ratio of 19.67. Nektar Therapeutics has a 52 week low of $30.30 and a 52 week high of $111.36.
Nektar Therapeutics Company Profile
Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.